The efficacy of Ankaferd Blood Stopper® in an experimental Asherman syndrome model created in rats

Basit Öğe Kaydı
dc.contributor.authorBuyuk, Basak
dc.contributor.authorBeyazit, Fatma
dc.date.accessioned2025-01-27T20:35:07Z
dc.date.available2025-01-27T20:35:07Z
dc.date.issued2019
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: Asherman syndrome (AS) is a progressive disease involving menstrual disorders, recurrent pregnancy losses, and infertility developing as a result of partial or full blockade of the uterine cavity with adhesions. AS generally develops after trauma to the basal layer of the endometrium. In spite of a variety of methods such as adhesiolysis, inserting intrauterine devices, and administering high doses of estrogen, treatments remain insufficient. This study aimed to assess the effects of local intrauterine Ankaferd Blood Stopper (ABS) administration in inducing endometrial proliferation and building a normal endometrial layer in a rat model. Materials and Methods: AS was induced in 30 female Wistar albino rats. The rats were randomized into three groups: Group 1: AS group Group 2: AS + serum physiologic (SP) group Group 3: AS + ABS group AS model was induced in all animals. The uterine horns were harvested after 15 days of therapy and investigated for inflammation, fibrosis, and immunohistochemical (IHC) markers. Results: Compared with the other groups, fibrosis, and inflammation were significantly reduced in group 3 (chi-square, p=19.000, 0.001 and 26.365, <0.001, respectively). The IHC assessment showed that the tumor necrosis factor-alpha receptor levels were not different (Kruskal-Wallis H=0.091, p=0.995), but the interleukin (IL)-1 beta and IL-6 expression was reduced significantly in group 3 (H, p=18.706, <0.001, and 22.114, <0.001, respectively). Conclusion: The therapeutic effects of local administration of ABS in rats with AS model were demonstrated histopathologically and immunohistochemically. Based on these results, ABS administration in addition to the current treatments for AS may increase the treatment success and reduce the need for advanced treatment.
dc.description.sponsorshipCanakkale Onsekiz Mart University Scientific Research Projects Coordination Unit [TSA-2016-1032]
dc.description.sponsorshipThis study was supported by Canakkale Onsekiz Mart University Scientific Research Projects Coordination Unit (project ID: TSA-2016-1032).
dc.identifier.doi10.4274/tjod.galenos.2018.21298
dc.identifier.endpage14
dc.identifier.issn2149-9322
dc.identifier.issn2149-9330
dc.identifier.issue1
dc.identifier.pmid31019834
dc.identifier.scopus2-s2.0-85088159991
dc.identifier.scopusqualityQ3
dc.identifier.startpage7
dc.identifier.trdizinid362853
dc.identifier.urihttps://doi.org/10.4274/tjod.galenos.2018.21298
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/362853
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23575
dc.identifier.volume16
dc.identifier.wosWOS:000462504300002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherGalenos Yayincilik
dc.relation.ispartofTurkish Journal of Obstetrics and Gynecology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectAsherman syndrome
dc.subjectintrauterine synechiae
dc.subjectfibrosis
dc.subjectinflammation
dc.titleThe efficacy of Ankaferd Blood Stopper® in an experimental Asherman syndrome model created in rats
dc.title.alternativeSıçanlarda oluşturulan deneysel asherman sendromu modelinde ankaferd blood stopper®’in etkinliğinin gösterilmesi
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu